Abstract: FR-PO100
Statins and Contrast Induced-AKI: A Systematic Review and Meta-Analysis
Session Information
- AKI: Epidemiology, Risk Factors, Prevention
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 101 AKI: Epidemiology‚ Risk Factors‚ and Prevention
Authors
- Chittoor, Shriman, Fort Bend Independent School District, Sugar Land, Texas, United States
- Kohli, Kripa, Fort Bend Independent School District, Sugar Land, Texas, United States
- Navaneethan, Sankar D., Baylor College of Medicine, Houston, Texas, United States
Background
Several treatment options are available to reduce the incidence of contrast-induced acute kidney injury (CI-AKI). Clinical trial evidence reported conflicting data on the incidence of CIN with statins. Hence, we conducted a systematic review and meta-analysis to evaluate the effects of statins as well as compare the effects of different doses of statins on the incidence of CI-AKI.
Methods
We searched MEDLINE and other databases (until March 2022) for randomized control trials (RCTs) that compared the effect of statin treatment on the incidence of CI-AKI or trials that compared high-dose vs. low-dose statin treatments on the occurrence of CI-AKI. Two authors independently assessed study quality and extracted data. Statistical analyses were performed using the random-effects model and results were expressed as a risk ratio (RR) for dichotomous outcomes with 95% confidence intervals (CI). Quality assessment was conducted using Cochrane quality assessment method.
Results
Seven RCTs (6635 patients) comparing statins to placebo and 2 trials (1204 patients) comparing low dose to high dose statins were included. There was a 59% reduction in the incidence of CIN with statins (7 trials, 6655 patients, Pooled RR- 0.59, 95% CI 0.44- 0.79) compared to placebo with no significant heterogeneity between the included studies [Figure]. However, there was no impact on the incidence of CI-AKI warranting dialysis with statins (Pooled RR- 0.28, 95% CI 0.05-1.70). High dose statins (vs. low dose statins) did not lower the incidence of CI-AKI (Pooled RR- 0.70, 95% CI 0.39-1.26) and CI-AKI warranting dialysis. Most included studies had mild-moderate risk of bias.
Conclusion
Statins use reduced the incidence of CI-AKI but without an impact on the incidence of AKI warranting dialysis. Large clinical trials examining the potential beneficial effects of high dose statins are warranted.
Incidence of CI-AKI with statins and placebo